-v5.svg)
-v5.svg)
An invaluable small-group learning opportunity for generalist neurologists on the latest approaches to MS management with Mavenclad® (cladribine tablets).
Mavenclad® Masterclass: Exclusive Insights from Leading Neurologists
NEUROLOGY EDUCATION
An invaluable small-group learning opportunity for generalist neurologists on the latest approaches to MS management with Mavenclad®
Mavenclad® Masterclass: Exclusive Insights from Leading Neurologists
CPD WEBINAR
Event countdown
Available Dates:
- Wednesday 12 March 2025
- Thursday 13 March 2025
Time: 7:30-8:30pm (AEDT) - see timezones
Location: Virtual, via the Praxhub platform. Access details will be confirmed upon registration. Attendees must use a laptop/PC with webcam and reliable internet to join the meetings.
Session Details
Merck Healthcare is pleased to offer this unique educational program for neurologists around Australia. Neurologists are invited to attend a single, virtual small-group discussion facilitated by a leading MS expert. Groups will be limited to no more than 10 attendees, allocated on a first-in first-served basis.
In this collaborative peer discussion, you'll:
- Deepen your understanding: Gain practical insights into optimising Mavenclad® treatment strategies.
- Explore complex cases: Analyse real-world scenarios and discuss best practices with leading MS experts.
- Share and learn: Engage in open discussions with peers and address those lingering questions you might have.
- Expand your network: Connect with fellow neurologists who share your passion for improving MS care.
About this education
Describe key determinants for selecting switch therapies in MS patients.
5
Demonstrate a framework for assessing menopausal symptom severity and for providing advice to women on options for optimal management.
1
Recall the clinical features,benefits and risks of Mavenclad® in MS treatment.
3
2
Identify optimal treatment options for new MS patients when considering symptoms, disease progression and patient characteristics.
4
Learning Outcomes
- Introductions
- Presentation: Optimising MS Treatment Strategies: A Rediscover of Mavenclad in Clinical Practice – 10 mins
- Case Study Presentations – 30 mins
- Discussion – 20 mins
Certificates of attendance will be provided for CME/CPD purposes.
Agenda
This education has been developed with a panel of leading experts. Each session will be led by one of the following:
Neurologist at St Vincent's Hospital, researcher in MS & neuroimmunology
Dr Jennifer Massey
Neurologist Eastern Health
Dr Katherine Buzzard
Neurologist at Alfred Health Neuroscientist at Monash Dept of Neuroscience.
Dr Mastura Monif
Neurologist & Neuroimmunologist, North Shore Private Hospital, CEO of CU Health
Dr Patrick Aouad
Education Steering Committee / Presenters
Register for this free small-group learning opportunity
This education is sponsored Merck Healthcare. All content is the true, accurate and independent opinion of the authors/presenters and the views expressed are entirely their own.
Mavenclad® PBS Information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.
Before prescribing Mavenclad®, please review the Full Product Information available from Merck (1800 633 463) or click here
© Praxhub 2025, all rights reserved.
Australian Eastern Daylightsaving Time: 7:30pm
Melbourne/Canberra/Sydney/Hobart (GMT+11)
Norfolk Island Daylight Time: 8:30pm
(GMT+12)
Australian Eastern Standard Time: 6:30pm
Brisbane (GMT+10)
Australian Central Daylight Time: 7:00pm
Adelaide (GMT+10.30)
Australian Western Standard Time: 4:30pm
Perth (GMT+8)
Christmas Island Time: 3:30pm
(GMT+7)